Latin America – Brazil, Mexico launch efforts to ease biosimilar regulation
In recent weeks, both Brazilian and Mexican regulatory authorities have made public their eagerness to spur domestic production – and faster regulation – of biosimilar drugs, with each country hoping to both reduce its own dependence on high-cost imported biologic agents and emerge as an important regional exporter of lower-cost therapies.
On 27 September, officials with Brazil’s National Health Surveillance Agency (ANVISA) announced a public comment period concerning a proposed rule change that would, if adopted, ease the path by which biologic and biosimilar drugs receive marketing authorization.
More information on RIS.World.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (12 mars 2024). Latin America – Brazil, Mexico launch efforts to ease biosimilar regulation. ELSIBI. Consulté le 11 octobre 2026 à l’adresse https://doi.org/10.58079/w0a4
